Johnson & Johnson (NYSE:JNJ) issued its earnings results on Wednesday. The company reported $1.88 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.87 by $0.01, RTT News reports. Johnson & Johnson had a net margin of 21.09% and a return on equity of 39.81%. The firm had revenue of $20.75 billion for the quarter, compared to the consensus estimate of $20.83 billion. During the same quarter in the prior year, the firm posted $1.97 earnings per share. The business’s revenue was up 1.7% on a year-over-year basis. Johnson & Johnson updated its FY 2020
Pre-Market guidance to 9.00-9.15 EPS and its FY20 guidance to $8.95-9.10 EPS.
Shares of JNJ stock opened at $149.27 on Wednesday. The company has a current ratio of 1.26, a quick ratio of 1.00 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a 12-month low of $125.00 and a 12-month high of $150.17. The stock has a market capitalization of $392.60 billion, a P/E ratio of 23.32, a P/E/G ratio of 2.40 and a beta of 0.71. The firm’s 50 day moving average is $144.44 and its 200 day moving average is $135.05.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 25th will be given a dividend of $0.95 per share. The ex-dividend date is Monday, February 24th. This represents a $3.80 dividend on an annualized basis and a yield of 2.55%. Johnson & Johnson’s dividend payout ratio (DPR) is 46.45%.
JNJ has been the subject of several analyst reports. Barclays raised shares of Johnson & Johnson from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $140.00 to $173.00 in a research report on Thursday, December 19th. Raymond James lowered their price objective on Johnson & Johnson from $146.00 to $145.00 and set an “outperform” rating on the stock in a research report on Monday, October 14th. Atlantic Securities upgraded Johnson & Johnson from an “underweight” rating to a “neutral” rating in a research note on Wednesday, October 16th. Wells Fargo & Co increased their target price on Johnson & Johnson from $155.00 to $165.00 and gave the company an “overweight” rating in a research note on Thursday, January 9th. Finally, Cantor Fitzgerald began coverage on Johnson & Johnson in a report on Wednesday, November 27th. They issued an “overweight” rating and a $160.00 target price for the company. Three research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Johnson & Johnson currently has a consensus rating of “Buy” and an average price target of $159.33.
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 2,017 shares of the firm’s stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $141.07, for a total value of $284,538.19. Following the transaction, the executive vice president now directly owns 51,736 shares of the company’s stock, valued at $7,298,397.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Hubert Joly bought 5,000 shares of the company’s stock in a transaction on Friday, December 13th. The stock was purchased at an average cost of $141.28 per share, for a total transaction of $706,400.00. Following the completion of the transaction, the director now directly owns 5,000 shares of the company’s stock, valued at approximately $706,400. The disclosure for this purchase can be found here. Insiders own 0.23% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Article: Pattern Day Trader
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.